| 发明名称 | Proteoglycan degrading mutants for treatment of CNS | ||
| 摘要 | The present disclosure relates to the preparation and deletion mutants of chondroitinase proteins and their use in methods for promoting the diffusion of therapeutic composition into tissues and their use for neurological functional recovery after central nervous system (“CNS”) injury or disease. | ||
| 申请公布号 | US9528102(B2) | 申请公布日期 | 2016.12.27 |
| 申请号 | US201414188679 | 申请日期 | 2014.02.24 |
| 申请人 | Acorda Therapeutics, Inc. | 发明人 | Gruskin Elliott A.;D'Souza Rohini;Roy Gargi;Caggiano Anthony O. |
| 分类号 | C12N15/60;C12N9/88;A61K38/51;C07K19/00;C12N9/26;C07K14/005;A61K35/30;A61K38/00 | 主分类号 | C12N15/60 |
| 代理机构 | Pepper Hamilton LLP | 代理人 | Pepper Hamilton LLP |
| 主权项 | 1. An isolated nucleic acid comprising a cDNA sequence that encodes for a mutant polypeptide of chondroitinase ABC I, wherein the mutant polypeptide is selected from SEQ ID NO: 2, SEQ ID NO: 3 or SEQ ID NO: 4. | ||
| 地址 | Ardsley NY US | ||